Page results
-
Information about clinic-based after-care following treatment for childhood or teenage cancer at UCLH.
-
This information page aims to answer some of the questions you may have about receiving chimeric antigen receptor (CAR) T-cell therapy at University College London Hospitals NHS Foundation Trust (UCLH).
-
Events, classes and workshops at the Macmillan Support and Information Service (MSIS)
-
Latest news and developments in the Macmillan Support and Information Service
-
The UCLH immunotherapy-neurotoxicity multidisciplinary service (IO-neurotox MDT) was established collaboratively between the National Hospital for Neurology and Neurosurgery (NHNN) and a nationwide oncology clinical team to offer high-quality diagnostic and management guidance on the care of cancer patients with, or suspected of having, any form of neurological complication of immunotherapy (immune-checkpoint inhibitor therapy).
-
Information about staff who work in the Macmillan Support and Information Service.
-
The first UK trial to test the benefits of proton beam therapy for certain patients with breast cancer has launched at UCLH.
-
This is information for women who have been given a diagnosis of adenomyosis.
-
Our annual members' meeting (AMM) brings together members, governors and staff, and is where our governors officially receive our annual report and accounts.
-
Once again, UCLH has received the highest score of all general acute and acute/community NHS trusts in England for staff that would recommend us as a place to work
File results
-
FOI/2021/0696 - Procurement of Robotic Process Automation (RPA)
-
FOI/2021/0704 - Language translation and interpreting services
-
FOI/2021/0708 - Treatment of dermatological conditions
-
FOI/2021/0713 - Incidence and treatment of Haemophilia A
-
FOI/2021/0714 - Data management systems of care testing devices
-
FOI/2021/0715 - Urothelial cancer treatment
-
FOI/2021/0716 - COVID-19 deaths
-
FOI/2021/0721 - Maternity units within your trust
-
FOI/2021/0723 - Covid 19 deaths
-
FOI/2021/0730 - Treatment with Ofatumumab